Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Frazier Healthcare
Biotech
Phathom's erosive esophagitis drug bests Prevacid in phase 3
Phathom Pharmaceuticals' erosive esophagitis drug vonoprazan performed as well as over-the-counter Prevacid in a head-to-head phase 3 clinical trial.
Emmy Lucas
Oct 18, 2021 3:10pm
Inipharm raises $35M to combat liver diseases
Nov 11, 2020 8:00am
Frazier closes $780M growth buyout fund
Apr 10, 2018 8:50am
Biotech vets tap Frazier, Alpine for cash for STING R&D
Nov 29, 2017 8:00am
Frazier hits $419M for early-stage biotech investments
Nov 1, 2017 5:00am
Iterum bags $65M for phase 3 trial of ex-Pfizer antibiotic
May 19, 2017 3:13am